376 related articles for article (PubMed ID: 32811512)
1. Targeting EphA2 in cancer.
Xiao T; Xiao Y; Wang W; Tang YY; Xiao Z; Su M
J Hematol Oncol; 2020 Aug; 13(1):114. PubMed ID: 32811512
[TBL] [Abstract][Full Text] [Related]
2. Silencing of EphA2 inhibits invasion of human gastric cancer SGC-7901 cells in vitro and in vivo.
Yuan W; Chen Z; Chen Z; Wu S; Guo J; Ge J; Yang P; Huang J
Neoplasma; 2012; 59(1):105-13. PubMed ID: 22103904
[TBL] [Abstract][Full Text] [Related]
3. C1GALT1 is associated with poor survival and promotes soluble Ephrin A1-mediated cell migration through activation of EPHA2 in gastric cancer.
Lee PC; Chen ST; Kuo TC; Lin TC; Lin MC; Huang J; Hung JS; Hsu CL; Juan HF; Lee PH; Huang MC
Oncogene; 2020 Mar; 39(13):2724-2740. PubMed ID: 32005975
[TBL] [Abstract][Full Text] [Related]
4. Human dendritic cells express neuronal Eph receptor tyrosine kinases: role of EphA2 in regulating adhesion to fibronectin.
de Saint-Vis B; Bouchet C; Gautier G; Valladeau J; Caux C; Garrone P
Blood; 2003 Dec; 102(13):4431-40. PubMed ID: 12907451
[TBL] [Abstract][Full Text] [Related]
5. The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization.
Ogawa K; Pasqualini R; Lindberg RA; Kain R; Freeman AL; Pasquale EB
Oncogene; 2000 Dec; 19(52):6043-52. PubMed ID: 11146556
[TBL] [Abstract][Full Text] [Related]
6. The EphA2 and cancer connection: potential for immune-based interventions.
London M; Gallo E
Mol Biol Rep; 2020 Oct; 47(10):8037-8048. PubMed ID: 32990903
[TBL] [Abstract][Full Text] [Related]
7. Small molecules can selectively inhibit ephrin binding to the EphA4 and EphA2 receptors.
Noberini R; Koolpe M; Peddibhotla S; Dahl R; Su Y; Cosford ND; Roth GP; Pasquale EB
J Biol Chem; 2008 Oct; 283(43):29461-72. PubMed ID: 18728010
[TBL] [Abstract][Full Text] [Related]
8. EphA2/Ephrin-A1 Mediate Corneal Epithelial Cell Compartmentalization via ADAM10 Regulation of EGFR Signaling.
Kaplan N; Ventrella R; Peng H; Pal-Ghosh S; Arvanitis C; Rappoport JZ; Mitchell BJ; Stepp MA; Lavker RM; Getsios S
Invest Ophthalmol Vis Sci; 2018 Jan; 59(1):393-406. PubMed ID: 29351356
[TBL] [Abstract][Full Text] [Related]
9. Protection by the Eph-Ephrin System Against Mesenteric Ischemia-Reperfusion Injury.
Vivo V; Zini I; Cantoni AM; Grandi A; Tognolini M; Castelli R; Ballabeni V; Bertoni S; Barocelli E
Shock; 2017 Dec; 48(6):681-689. PubMed ID: 28472014
[TBL] [Abstract][Full Text] [Related]
10. EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer.
Martini G; Cardone C; Vitiello PP; Belli V; Napolitano S; Troiani T; Ciardiello D; Della Corte CM; Morgillo F; Matrone N; Sforza V; Papaccio G; Desiderio V; Paul MC; Moreno-Viedma V; Normanno N; Rachiglio AM; Tirino V; Maiello E; Latiano TP; Rizzi D; Signoriello G; Sibilia M; Ciardiello F; Martinelli E
Mol Cancer Ther; 2019 Apr; 18(4):845-855. PubMed ID: 30824612
[TBL] [Abstract][Full Text] [Related]
11. Ligation of EphA2 by Ephrin A1-Fc inhibits pancreatic adenocarcinoma cellular invasiveness.
Duxbury MS; Ito H; Zinner MJ; Ashley SW; Whang EE
Biochem Biophys Res Commun; 2004 Aug; 320(4):1096-102. PubMed ID: 15249202
[TBL] [Abstract][Full Text] [Related]
12. EphA2 stimulates VCAM-1 expression through calcium-dependent NFAT1 activity.
Funk SD; Finney AC; Yurdagul A; Pattillo CB; Orr AW
Cell Signal; 2018 Sep; 49():30-38. PubMed ID: 29793020
[TBL] [Abstract][Full Text] [Related]
13. Ephrin-A1 is a negative regulator in glioma through down-regulation of EphA2 and FAK.
Liu DP; Wang Y; Koeffler HP; Xie D
Int J Oncol; 2007 Apr; 30(4):865-71. PubMed ID: 17332925
[TBL] [Abstract][Full Text] [Related]
14. EphA2 receptor activation with ephrin-A1 ligand restores cetuximab efficacy in NRAS-mutant colorectal cancer cells.
Cuyàs E; Queralt B; Martin-Castillo B; Bosch-Barrera J; Menendez JA
Oncol Rep; 2017 Jul; 38(1):263-270. PubMed ID: 28560458
[TBL] [Abstract][Full Text] [Related]
15. Ligand recognition by A-class Eph receptors: crystal structures of the EphA2 ligand-binding domain and the EphA2/ephrin-A1 complex.
Himanen JP; Goldgur Y; Miao H; Myshkin E; Guo H; Buck M; Nguyen M; Rajashankar KR; Wang B; Nikolov DB
EMBO Rep; 2009 Jul; 10(7):722-8. PubMed ID: 19525919
[TBL] [Abstract][Full Text] [Related]
16. Nanoscale obstacle arrays frustrate transport of EphA2-Ephrin-A1 clusters in cancer cell lines.
Lohmüller T; Xu Q; Groves JT
Nano Lett; 2013 Jul; 13(7):3059-64. PubMed ID: 23668885
[TBL] [Abstract][Full Text] [Related]
17. Targeting EphA2 impairs cell cycle progression and growth of basal-like/triple-negative breast cancers.
Song W; Hwang Y; Youngblood VM; Cook RS; Balko JM; Chen J; Brantley-Sieders DM
Oncogene; 2017 Oct; 36(40):5620-5630. PubMed ID: 28581527
[TBL] [Abstract][Full Text] [Related]
18. May EPH/Ephrin Targeting Revolutionize Lung Cancer Treatment?
Psilopatis I; Karniadakis I; Danos KS; Vrettou K; Michaelidou K; Mavridis K; Agelaki S; Theocharis S
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613532
[TBL] [Abstract][Full Text] [Related]
19. Ligand targeting of EphA2 enhances keratinocyte adhesion and differentiation via desmoglein 1.
Lin S; Gordon K; Kaplan N; Getsios S
Mol Biol Cell; 2010 Nov; 21(22):3902-14. PubMed ID: 20861311
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment.
Nishimura M; Jung EJ; Shah MY; Lu C; Spizzo R; Shimizu M; Han HD; Ivan C; Rossi S; Zhang X; Nicoloso MS; Wu SY; Almeida MI; Bottsford-Miller J; Pecot CV; Zand B; Matsuo K; Shahzad MM; Jennings NB; Rodriguez-Aguayo C; Lopez-Berestein G; Sood AK; Calin GA
Cancer Discov; 2013 Nov; 3(11):1302-15. PubMed ID: 24002999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]